Page last updated: 2024-09-03

up 269-6 and losartan

up 269-6 has been researched along with losartan in 11 studies

Compound Research Comparison

Studies
(up 269-6)
Trials
(up 269-6)
Recent Studies (post-2010)
(up 269-6)
Studies
(losartan)
Trials
(losartan)
Recent Studies (post-2010) (losartan)
15407,2311,2452,118

Protein Interaction Comparison

ProteinTaxonomyup 269-6 (IC50)losartan (IC50)
Bile salt export pumpHomo sapiens (human)9.01
Cytochrome P450 2C9 Homo sapiens (human)2.882
Angiotensin-converting enzyme Homo sapiens (human)0.019
Atrial natriuretic peptide receptor 3Homo sapiens (human)0.0018
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)0.019
Type-1A angiotensin II receptor Rattus norvegicus (Norway rat)0.0247
Type-1B angiotensin II receptorRattus norvegicus (Norway rat)0.0234
Adenosine receptor A2aRattus norvegicus (Norway rat)0.0032
Type-1 angiotensin II receptorHomo sapiens (human)0.047
Type-1 angiotensin II receptorOryctolagus cuniculus (rabbit)0.025
Type-2 angiotensin II receptorRattus norvegicus (Norway rat)0.0118
Type-2 angiotensin II receptorHomo sapiens (human)0.019
Platelet glycoprotein VIHomo sapiens (human)4
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)1.1481
Type-1 angiotensin II receptorCavia porcellus (domestic guinea pig)0.018
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)0.2884

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's6 (54.55)18.2507
2000's4 (36.36)29.6817
2010's1 (9.09)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Caussade, F; Cazes, M; Cloarec, A; Curé, G; Goyard, J; Kirchner, M; Nicolaï, E; Teulon, JM; Versigny, A; Virone-Oddos, A1
Goldberg, MR; Greenlee, WJ; Irvin, JD; Prendergast, K; Smith, RD; Timmermans, PB; Wexler, RR1
Giridhar, R; Murumkar, P; Naik, P; Yadav, MR1
Caussade, F; Cazes, M; Cloarec, A; Delchambre, C; Versigny, A; Virone-Oddos, A1
Cazes, M; Cloarec, A; Provost, D; Versigny, A1
Caussade, F; Cazes, M; Cloarec, A; Desangle, V; Provost, D; Virone-Oddos, A1
Mutschler, E; Palm, D; Soldner, A; Spahn-Langguth, H1
Jugdutt, BI; Menon, V; O'Brien, DW; Xu, Y1
Jugdutt, BI; Kumar, D; Menon, V; Moudgil, R; Musat-Marcu, S; Xu, Y1
Jugdutt, BI; Menon, V; Moudgil, R; Xu, Y1
Jugdutt, BI; Menon, V; Xu, Y1

Reviews

2 review(s) available for up 269-6 and losartan

ArticleYear
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
    Journal of medicinal chemistry, 1996, Feb-02, Volume: 39, Issue:3

    Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Humans; Receptors, Angiotensin; Structure-Activity Relationship

1996
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
    Bioorganic & medicinal chemistry, 2010, Dec-15, Volume: 18, Issue:24

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Losartan

2010

Trials

1 trial(s) available for up 269-6 and losartan

ArticleYear
A radioreceptor assay for the analysis of AT1-receptor antagonists. Correlation with complementary LC data reveals a potential contribution of active metabolites.
    Journal of pharmaceutical and biomedical analysis, 1998, Volume: 17, Issue:1

    Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Proteins; Chromatography, High Pressure Liquid; Double-Blind Method; Humans; Imidazoles; Losartan; Male; Placebos; Pyrimidines; Radioligand Assay; Rats; Rats, Wistar; Receptors, Angiotensin; Reference Values; Sensitivity and Specificity; Tetrazoles

1998

Other Studies

8 other study(ies) available for up 269-6 and losartan

ArticleYear
Synthesis and SAR studies of novel triazolopyrimidine derivatives as potent, orally active angiotensin II receptor antagonists.
    Journal of medicinal chemistry, 1994, Jul-22, Volume: 37, Issue:15

    Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Azoles; Hypertension; Male; Models, Molecular; Pyrimidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tetrazoles

1994
In vitro pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist.
    Fundamental & clinical pharmacology, 1995, Volume: 9, Issue:2

    Topics: Adrenal Medulla; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Binding, Competitive; Biphenyl Compounds; Dose-Response Relationship, Drug; Imidazoles; In Vitro Techniques; Losartan; Male; Muscle, Smooth, Vascular; Pyrimidines; Radioligand Assay; Rats; Tetrazoles

1995
In vivo pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist.
    European journal of pharmacology, 1995, Sep-15, Volume: 284, Issue:1-2

    Topics: Administration, Oral; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Decerebrate State; Dogs; Dose-Response Relationship, Drug; Heart Rate; Imidazoles; Injections, Intravenous; Losartan; Male; Pyrimidines; Rats; Rats, Sprague-Dawley; Species Specificity; Tetrazoles; Vasoconstrictor Agents

1995
In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation.
    British journal of pharmacology, 1997, Volume: 120, Issue:3

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Carotid Arteries; Carotid Artery Injuries; Catheterization; Cell Division; Imidazoles; In Vitro Techniques; Losartan; Muscle Proteins; Muscle, Smooth, Vascular; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Wistar; Stimulation, Chemical; Tetrazoles

1997
Efficacy of pretreatment with the angiotensin II type 1 receptor blocker UP269-6 and losartan in the dog: effect on hemodynamics and ischemia-reperfusion.
    Journal of cardiovascular pharmacology and therapeutics, 2000, Volume: 5, Issue:2

    Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Animals; Dogs; Dose-Response Relationship, Drug; Female; Hemodynamics; Losartan; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Pyrimidines; Random Allocation; Receptors, Angiotensin; Tetrazoles

2000
Postischemic apoptosis and functional recovery after angiotensin II type 1 receptor blockade in isolated working rat hearts.
    Journal of hypertension, 2001, Volume: 19, Issue:6

    Topics: Angiotensin Receptor Antagonists; Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspases; In Vitro Techniques; Losartan; Male; Myocardial Reperfusion Injury; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Tetrazoles; Tumor Suppressor Protein p53; Ventricular Function, Left

2001
Effect of chronic AT(1) receptor antagonism on postischemic functional recovery and AT(1)/AT(2) receptor proteins in isolated working rat hearts.
    Journal of cardiovascular pharmacology and therapeutics, 2001, Volume: 6, Issue:2

    Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Animals; Heart; In Vitro Techniques; Losartan; Male; Myocardial Ischemia; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles

2001
Cardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C-epsilon in acutely reperfused myocardial infarction in the dog. Effect of UP269-6 and losartan on AT1 and AT2-recep
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2000, Volume: 1, Issue:2

    Topics: Angiotensin Receptor Antagonists; Animals; Blood Volume; Calcium Channels; Cardiotonic Agents; Cyclic GMP; Dogs; Enzyme Activation; Female; Hemodynamics; Inositol 1,4,5-Trisphosphate Receptors; Isoenzymes; Losartan; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Protein Kinase C; Protein Kinase C-epsilon; Pyrimidines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Tetrazoles; Time Factors; Ventricular Function, Left

2000